BACKGROUND: Reduced metabolic activity improves outcome in many clinical and experimental models of injury and diseases that result in insufficient blood supply. Recently, we demonstrated that inhaled hydrogen sulfide gas can be used to reversibly reduce metabolic activity in mice. We hypothesize that hydrogen sulfide will confer benefit in injuries and diseases related to insufficient blood supply. METHODS: Sprague-Dawley rats were subjected to controlled hemorrhage to remove 60% of total blood. Hydrogen sulfide was administered to rats either via airway as gas, or intravenous infusion as liquid. Outcome was assayed by survival. RESULTS: Using inhaled hydrogen sulfide gas, 75% of treated and 23% of untreated rats survived longer than 24 hours. Using intravenous administered sulfide, 67% of treated and 14% of untreated rats survived longer than 24 hours. Using log-rank analysis, p < 0.001. Surviving rats showed no functional or behavioral abnormalities. Blood chemistry analysis at the end of hemorrhage showed minor but significant differences between treated and control animals. Respirometry results show that hydrogen sulfide stabilized metabolic output during and after hemorrhage. CONCLUSION: These data indicate that sulfide can protect rats from lethal hemorrhage. Future studies are needed to analyze the mechanism of benefit as well as whether sulfide is beneficial in other models of human injury and disease.
BACKGROUND: Reduced metabolic activity improves outcome in many clinical and experimental models of injury and diseases that result in insufficient blood supply. Recently, we demonstrated that inhaled hydrogen sulfide gas can be used to reversibly reduce metabolic activity in mice. We hypothesize that hydrogen sulfide will confer benefit in injuries and diseases related to insufficient blood supply. METHODS:Sprague-Dawley rats were subjected to controlled hemorrhage to remove 60% of total blood. Hydrogen sulfide was administered to rats either via airway as gas, or intravenous infusion as liquid. Outcome was assayed by survival. RESULTS: Using inhaled hydrogen sulfide gas, 75% of treated and 23% of untreated rats survived longer than 24 hours. Using intravenous administered sulfide, 67% of treated and 14% of untreated rats survived longer than 24 hours. Using log-rank analysis, p < 0.001. Surviving rats showed no functional or behavioral abnormalities. Blood chemistry analysis at the end of hemorrhage showed minor but significant differences between treated and control animals. Respirometry results show that hydrogen sulfide stabilized metabolic output during and after hemorrhage. CONCLUSION: These data indicate that sulfide can protect rats from lethal hemorrhage. Future studies are needed to analyze the mechanism of benefit as well as whether sulfide is beneficial in other models of humaninjury and disease.
Authors: Timothy J George; George J Arnaoutakis; Claude A Beaty; Simran K Jandu; Lakshmi Santhanam; Dan E Berkowitz; Ashish S Shah Journal: J Surg Res Date: 2012-06-27 Impact factor: 2.192
Authors: Katalin Módis; Eelke M Bos; Enrico Calzia; Harry van Goor; Ciro Coletta; Andreas Papapetropoulos; Mark R Hellmich; Peter Radermacher; Frédéric Bouillaud; Csaba Szabo Journal: Br J Pharmacol Date: 2014-04 Impact factor: 8.739
Authors: Oscar McCook; Peter Radermacher; Chiara Volani; Pierre Asfar; Anita Ignatius; Julia Kemmler; Peter Möller; Csaba Szabó; Matthew Whiteman; Mark E Wood; Rui Wang; Michael Georgieff; Ulrich Wachter Journal: Nitric Oxide Date: 2014-03-18 Impact factor: 4.427
Authors: Shizuka Minamishima; Masahiko Bougaki; Patrick Y Sips; Jia De Yu; Yoji Andrew Minamishima; John W Elrod; David J Lefer; Kenneth D Bloch; Fumito Ichinose Journal: Circulation Date: 2009-08-24 Impact factor: 29.690
Authors: Eelke M Bos; Rui Wang; Pauline M Snijder; Miriam Boersema; Jeffrey Damman; Ming Fu; Jill Moser; Jan-Luuk Hillebrands; Rutger J Ploeg; Guangdong Yang; Henri G D Leuvenink; Harry van Goor Journal: J Am Soc Nephrol Date: 2013-02-28 Impact factor: 10.121
Authors: Eelke M Bos; Henri G D Leuvenink; Pauline M Snijder; Niels J Kloosterhuis; Jan-Luuk Hillebrands; Jaklien C Leemans; Sandrine Florquin; Harry van Goor Journal: J Am Soc Nephrol Date: 2009-07-23 Impact factor: 10.121